Want to see ADAG full AI Analyst Report?
ADAG Stock Chart & Stats
$3.20
$0.33(10.31%)
At close: 4:00 PM EDT
$3.20
$0.33(10.31%)
Day’s Range― - ―
52-Week Range$1.30 - $4.85
Previous Close$3.53
Volume199.41K
Average Volume (3M)289.64K
Market Cap
$177.70M
Enterprise Value$37.85
Total Cash (Recent Filing)$74.52M
Total Debt (Recent Filing)$6.26M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Sep 02, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding66,072,590
10 Day Avg. Volume166,583
30 Day Avg. Volume289,638
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.02
Price to Sales (P/S)9.30
P/FCF Ratio-4.55
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside212.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.71
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Antibody PlatformAdagene’s proprietary antibody discovery and engineering platform is a durable strategic asset that continually generates novel therapeutic candidates. A robust platform increases probability of internal pipeline progression and attractive collaboration opportunities over multiple years, underpinning sustained R&D productivity and licensing value.
Partnership/licensing Revenue ModelThe company’s business model emphasizes upfronts, R&D reimbursements, milestones and potential royalties, enabling non-commercial revenue before product approval. This structure provides recurring funding touchpoints from partners, reducing sole reliance on product sales and supporting development spending through alliances over the medium term.
Improved Liquidity And Manageable LeverageA reported preliminary cash balance (~$127.9M as of June 30, 2026) combined with an improving debt-to-equity (0.18 in 2025) materially reduces near-term refinancing pressure. Stronger liquidity and low leverage give the company more runway to advance clinical programs and negotiate deals without immediate dilutive financings.
Bears Say
Persistent Cash BurnOperating and free cash flow have been negative across all reported years, indicating structural cash burn. Continued negative cash generation forces reliance on external financing or partner payments, raising dilution and execution risk if milestone timing or funding access falters over the next several quarters.
Volatile Revenue And Gross ProfitRevenue and gross profit swings (including a negative gross profit year) create unpredictability in cash runway and make it harder to model sustainable margins. Variable revenue quality reduces confidence in recurring partner income and complicates long-term planning for R&D prioritization and resource allocation.
Ongoing Losses And Negative ROEPersistent operating and net losses have produced consistently negative returns on equity, indicating the company is not yet earning its cost of capital. Until profitability improves, shareholders face dilution risk from future financings and limited capacity to deliver durable capital returns.
Adagene News
ADAG FAQ
What was Adagene’s price range in the past 12 months?
Adagene lowest stock price was $1.30 and its highest was $4.85 in the past 12 months.
What is Adagene’s market cap?
Adagene’s market cap is $177.70M.
When is Adagene’s upcoming earnings report date?
Adagene’s upcoming earnings report date is Sep 02, 2026 which is in 31 days.
How were Adagene’s earnings last quarter?
Adagene released its earnings results on Apr 01, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.1 by $0.02.
Is Adagene overvalued?
According to Wall Street analysts Adagene’s price is currently Undervalued.
Does Adagene pay dividends?
Adagene does not currently pay dividends.
What is Adagene’s EPS estimate?
Adagene’s EPS estimate is -0.19.
How many shares outstanding does Adagene have?
Adagene has 66,072,590 shares outstanding.
What happened to Adagene’s price movement after its last earnings report?
Adagene reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.1. Following the earnings report the stock price went down -13.449%.
Which hedge fund is a major shareholder of Adagene?
Currently, no hedge funds are holding shares in ADAG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adagene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (212.50% Upside)
$10.00 (212.50% Upside)
Blogger Sentiment
Bullish
ADAG Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.33%
Trailing 12-Months
Company Description
Adagene
Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.
ADAG Stock 12 Month Forecast
Average Price Target
$10.00
▲(212.50% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
3.72% Other Institutional Investors
96.20% Public Companies and
Individual Investors